Leerink Partners analyst Richard Newitter maintained a Buy rating on Zimmer Biomet Holdings (ZBH) today and set a price target of $136.00. The company’s shares closed last Tuesday at $119.20.
According to TipRanks.com, Newitter is a 5-star analyst with an average return of 22.5% and a 66.3% success rate. Newitter covers the Healthcare sector, focusing on stocks such as Intuitive Surgical, Becton Dickinson, and Globus Medical.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Zimmer Biomet Holdings with a $134.67 average price target, which is a 10.5% upside from current levels. In a report issued on April 28, Oppenheimer also maintained a Buy rating on the stock with a $141.00 price target.
See today’s analyst top recommended stocks >>
Zimmer Biomet Holdings’ market cap is currently $24.39B and has a P/E ratio of 22.30. The company has a Price to Book ratio of -5.64.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Zimmer Biomet Holdings, Inc. provides musculoskeletal healthcare services. It designs, manufactures and markets orthopedic reconstructive products, sports medicine, biologics, extremities & trauma products, office based technologies, spine, craniomaxillofacial & thoracic products, dental implants and related surgical products. Its products and solutions help treat patients suffering from disorders of, or injuries to, bones, joints or supporting soft tissues. Zimmer Biomet Holdings was founded by Justin O. Zimmer in 1927 and is headquartered in Warsaw, IN.
